The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 12, 2000, Pages 79-85

  Treon, S P ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; RITUXIMAB; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; AUTOIMMUNE HEMOLYTIC ANEMIA; CELL DIFFERENTIATION; CELL MATURATION; CONFERENCE PAPER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MULTIPLE MYELOMA; PLASMA CELL; POLYNEUROPATHY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN M; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TRANSCRIPTION FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 0034468110     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma
2. Katnofsky lecture: Immunotherapy of lymphoma
3. Anti-B4-blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma
4. Treatment of plasma cell dyscrasias by antibody mediated immunotherapy
5. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody
6. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma
7. Anti-CD54 (ICAM-1) has antitumour activity in SCID mice with human myeloma cells
8. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24
9. MUC-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
10. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes
11. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
12. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3′ enhancer activity
13. The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines
14. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator
15. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1
16. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes
17. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell
18. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction
19. Circulating clonotypic B cells in the biology of multiple myeloma: Speculations on the origin of myeloma
20. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation
21. + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells
22. + B lineage in Waldenström's macroglobulinemia
23. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
24. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells
25. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma
26. Phenotyping of circulating myeloma cells
27. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain
28. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells
29. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
30. Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells
31. Immunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease
32. Tumor cell heterogeneity in multiple myeloma: Antigenic, morphologic, and functional studies of cells from blood and bone marrow
33. Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies
34. Phase II study of rituximab in previously treated patients with multiple myeloma
35. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma patients
36. Rituximab therapy in previously treated Waldenström's macroglobulinemia: Preliminary evidence of clinical activity
37. Phenotypic and clinical evidence supports rituximab for Waldenström's macroglobulinemia
38. Rituximab is an active agent in Waldenström's macroglobulinemia
39. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
40. Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry
41. Phenotypic difference of normal plasma cells from mature myeloma cells
42. Update of response to rituximab of chronic relapsing ITP
43. CD20 monoclonal antibodies downregulate IgM at the surface of B cells
44. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab
45. Paraproteinemia and neuropathy
46. Thrombocytopenia with platelet associated IgM antibodies: Patient characteristics and responsiveness to ITP
47. Rituximab for the treatment of refractory immune thrombocytopenic purpura
48. Rituxan in the treatment of cold agglutinin disease
49. Use of anti-CD20 monoclonal antibody for the treatment of Evans syndrome and monoclonal gammopathy/neuropathy syndrome